Showing results (241-250 of 438) with videos related to
Sort By:
Pageof 44
Bone Marrow Transplantation|October 29, 2013
Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donorsA A Langston, J M Prichard, S Muppidi, et al.CPT: Pharmacometrics & Systems Pharmacology|April 16, 2024
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX studyRong Deng, Leonid Gibiansky, Tong Lu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2018
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline UpdateRandy A Taplitz, Erin B Kennedy, Eric J Bow, et al.American Journal of Hematology|May 10, 2023
Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapyAng Li, Sarah B May, Jennifer La, et al.Transfusion|May 26, 2012
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphomaJonathan L Kaufman, Christopher R Flowers, Karen D Rados, et al.JNCI Cancer Spectrum|July 25, 2024
Neighborhood-level social determinants of health burden among adolescent and young adult cancer patients and impact on overall survivalElizabeth R Rodriguez, Tori Tonn, Midhat Jafry, et al.Haematologica|September 28, 2023
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II studyChristopher R Flowers, Matthew J Matasar, Alex F Herrera, et al.Lancet (London, England)|August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trialsDai Chihara, Ruitao Lin, Christopher R Flowers, et al.Blood Advances|July 6, 2022
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysisDanny Luan, Tolulope Fatola, Ahmed Toure, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer InstituteDai Chihara, Erich P Huang, Shanda R Finnigan, et al.Pageof 44